Health Canada Approves CASGEVY (Exagamglogene Autotemcel), The First CRISPR/Cas9 Gene-Edited Therapy, For Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia In Patients 12 And Older
Portfolio Pulse from Benzinga Newsdesk
Health Canada has approved CASGEVY (Exagamglogene Autotemcel), the first CRISPR/Cas9 gene-edited therapy, for treating sickle cell disease and transfusion-dependent beta thalassemia in patients aged 12 and older. This approval marks a significant milestone in gene therapy.
September 25, 2024 | 7:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CRISPR Therapeutics, a key player in gene-editing technology, sees a major milestone with Health Canada's approval of CASGEVY, the first CRISPR/Cas9 therapy for sickle cell disease and beta thalassemia.
CRISPR Therapeutics is directly involved in the development of CASGEVY, and the approval by Health Canada is a significant regulatory milestone that could positively impact the company's stock price.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Vertex Pharmaceuticals, in collaboration with CRISPR Therapeutics, benefits from Health Canada's approval of CASGEVY, marking a significant advancement in gene therapy for sickle cell disease and beta thalassemia.
Vertex Pharmaceuticals collaborates with CRISPR Therapeutics on CASGEVY. The approval is a positive development for Vertex, potentially boosting its market position in gene therapy.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 80